Returning guest, Dr. Jeremy Levin, Chairman and CEO of Ovid Therapeutics, Inc., and former chairman of the global Biotechnology Innovation Organization (BIO) discusses the new COVID variant Delta-Plus, a virus that mutated from the highly infective Delta version, and why vaccinations are so crucial.
Dr. Ryan Mathis, MD, Vice President of Commercial Strategy at PolarityTE discusses SkinTE™ an innovative alternative for the treatment of chronic wounds, like diabetic foot ulcers (DFUs). He talks about the science behind SkinTE™, how it’s made of a patient’s own full-thickness skin, which retains the endogenous regenerative cellular populations found throughout his/her skin within multicellular segments. He also shares information from real-world studies of difficult to treat wounds. SkinTE™ is on track for IND submission in the second half of 2021.
Returning guest, Dr. Bruce Sands, M.D., M.S., Chief of the Dr. Henry D. Janowitz Division of Gastroenterology at Mount Sinai Hospital and the Dr. Burrill B. Crohn Professor of Medicine (Gastroenterology), at the Icahn Institute for Medicine at Mount Sinai discusses new data presented at the 16th Congress of European Crohn’s and Colitis Organisation (ECCO) from a trial evaluating biologic induction and maintenance therapy for moderately to severely active ulcerative colitis.
Leon Lerman, CEO of Cynerio, the leading provider of Healthcare IoT cybersecurity and asset management solutions discusses the biggest security challenges for healthcare in a post-COVID environment, why health systems should move to the Zero Trust model to secure their systems and devices, and whether governing bodies should provide cybersecurity requirements for healthcare.
Returning guest, Dr. Gregg Sylvester, Chief Medical Officer at Seqirus, a global leader in influenza prevention, discusses data from a first-of-its-kind co-administration study conducted by Novavax of the SARS-CoV-2 vaccine candidate (Novavax, NVX-CoV2373) and an approved influenza vaccine (Seqirus, Flucelvax Quadrivalent and Fluad). He talks about the potential advantages for patients and physicians to co-administer an approved COVID-19 and influenza vaccine, how these findings may impact proposed immunization scheduling for varying age groups and alter CDC recommendations, and the importance of these findings as we approach a critical 2021/22 influenza season while many populations are still in need of a primary COVID-19 vaccine series or booster dose.
Mike Lipps, CEO of Intelerad, a global leader in medical image management discusses why hospitals and health systems need fewer integrations to be able to truly manage their data and images and how a greater focus on data analytics can improve collaborative care. He also talks about the company’s recent growth and momentum that furthers the company’s mission to provide customers with the most comprehensive enterprise imaging platform in the industry.
Dr. Rajesh Rajpal, MD, Global Head of Clinical and Medical Affairs, Johnson & Johnson Vision discusses the launch and availability of their TECNIS Synergy™ in the United States and Canada. This next-generation presbyopia-correcting intraocular (PC-IOL) lens offers cataract patients the widest range of continuous vision, and best near vision among leading PC-IOLs, without the visual gaps seen with some multifocal technology. He talks about how this new next-gen lens was developed, designed, and the science behind it, as well as other innovations in eye care solutions.
Dr. Clive Ward-Able is the Medical & Scientific Affairs Consultant of NeonMind Biosciences, a company exploring psilocybin as an alternative approach to weight loss and appetite suppression. He shares his insights on the potential of psychedelics in the treatment of obesity, the current trials underway, and what the future may hold.
Dr. Karan Desai, MD, hand and upper extremity surgeon at Orlando Health Jewett Orthopedic Institute discusses how care for serious injuries at a level 1 trauma center can make the difference between amputation and recovery. He recently saved the arm of a paramedic that was bitten by an alligator.
Dr. Juan Camilo Arjona Ferreira, Chief Medical Officer of Myovant Sciences discusses uterine fibroids and the recent FDA approval of MYFEMBREE® for the treatment of heavy menstrual bleeding associated with uterine fibroids. MYFEMBREE is also being studied in endometriosis.